The gene-editing breakthrough announced Monday by Intellia Therapeutics and its partner Regeneron sparked another rally for biotech stocks, but it also cemented a comeback for Cathie Wood, founder of Ark Investment Management, which saw the AUM of its family of actively-managed ETFs explode over the past year thanks to her bets on crypto, Tesla, Shopify, Zoom, Palantir, Roblox.

Ark is the largest, or second-largest, shareholder of the handful of Crispr gene-editing technology companies that saw their shares rally hard on the news - including Crispr Therapeutics, Intellia, Editas Medicine and Beam Therapeutics - and the news sent shares of the Ark Genomic Revolution ETF up 3.3% on Monday while Ark's flagship Ark Innovation fund rallied 3.8%.

The rally cemented a comeback of sorts for Wood. After a rough few months, Ark's flagship fund has now rallied more than 25% off its May low.

So, with everything going swimmingly, Wood surprised skeptical investors and fans alike on Monday when Ark submitted a prospectus petitioning the SEC for permission to launch a bitcoin ETF in partnership with 21Shares (which has launched bitcoin ETNs in Europe). Of course, the SEC's unwillingness to authorize a bitcoin ETF is already widely known. Ark's application marks the 12th petition for permission to launch a bitcoin ETF, according to Bloomberg's Eric Balchunas.